| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Novartis AG (NYSE: NVS)
NVS Technical Analysis
5
| As on 9th Jun 2023 NVS SHARE Price closed @ 100.93 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 84.89 & Strong Buy for SHORT-TERM with Stoploss of 86.87 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NVSSHARE Price
| Open | 100.35 | Change | Price | % |
| High | 101.03 | 1 Day | 0.28 | 0.28 |
| Low | 99.68 | 1 Week | 4.68 | 4.86 |
| Close | 100.93 | 1 Month | -1.72 | -1.68 |
| Volume | 3167400 | 1 Year | 14.94 | 17.37 |
| 52 Week High 104.91 | 52 Week Low 74.61 | ||||
NYSE USA Most Active Stocks
| DDR | 15.44 | -4.46% |
| NIO | 7.73 | -0.77% |
| TWTR | 53.70 | 0.66% |
| CVNA | 19.07 | -21.30% |
| BACA-U | 302.00 | 0.67% |
| PLTR | 15.02 | -1.12% |
| F | 13.74 | 1.18% |
| CS | 0.89 | 1.14% |
| RPAI | 13.15 | -3.17% |
| AUY | 5.85 | -0.68% |
NYSE USA Top Gainers Stocks
NYSE USA Top Losers Stocks
| NVS Daily Charts |
NVS Intraday Charts |
Whats New @ Bazaartrend |
NVS Free Analysis |
|
|
NVS Important Levels Intraday
| RESISTANCE | 103.53 |
| RESISTANCE | 102.70 |
| RESISTANCE | 102.18 |
| RESISTANCE | 101.67 |
| SUPPORT | 100.19 |
| SUPPORT | 99.68 |
| SUPPORT | 99.16 |
| SUPPORT | 98.33 |
NVS Forecast April 2024
| 4th UP Forecast | 115.81 |
| 3rd UP Forecast | 111.04 |
| 2nd UP Forecast | 108.09 |
| 1st UP Forecast | 105.14 |
| 1st DOWN Forecast | 96.72 |
| 2nd DOWN Forecast | 93.77 |
| 3rd DOWN Forecast | 90.82 |
| 4th DOWN Forecast | 86.05 |
NVS Weekly Forecast
| 4th UP Forecast | 103.34 |
| 3rd UP Forecast | 102.57 |
| 2nd UP Forecast | 102.09 |
| 1st UP Forecast | 101.61 |
| 1st DOWN Forecast | 100.25 |
| 2nd DOWN Forecast | 99.77 |
| 3rd DOWN Forecast | 99.29 |
| 4th DOWN Forecast | 98.52 |
NVS Forecast2024
| 4th UP Forecast | 161.57 |
| 3rd UP Forecast | 142.12 |
| 2nd UP Forecast | 130.1 |
| 1st UP Forecast | 118.08 |
| 1st DOWN Forecast | 83.78 |
| 2nd DOWN Forecast | 71.76 |
| 3rd DOWN Forecast | 59.74 |
| 4th DOWN Forecast | 40.29 |
Novartis AG ( NYSE USA Symbol : NVS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NVS Business Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Address: Lichtstrasse 35, Basel, Switzerland, 4056
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service